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Leishmaniasis is the third most important vector-borne disease worldwide. Visceral leish-
maniasis (VL) is a severe and frequently lethal protozoan disease of increasing incidence
and severity due to infected human and dogmigration, new geographical distribution of the
insect due to global warming, coinfection with immunosuppressive diseases, and poverty.
The disease is an anthroponosis in India and Central Africa and a canid zoonosis (ZVL) in
the Americas, the Middle East, Central Asia, China, and the Mediterranean. The ZVL epi-
demic has been controlled by one or more measures including the culling of infected dogs,
treatment of human cases, and insecticidal treatment of homes and dogs. However, the
use of vaccines is considered the most cost–effective control tool for human and canine
disease. Since the severity of the disease is related to the generation of T-cell immuno-
suppression, effective vaccines should be capable of sustaining or enhancing the T-cell
immunity. In this review we summarize the clinical and parasitological characteristics of
ZVL with special focus on the cellular and humoral canine immune response and review
state-of-the-art vaccine development against human and canine VL. Experimental vacci-
nation against leishmaniasis has evolved from the practice of leishmanization with living
parasites to vaccination with crude lysates, native parasite extracts to recombinant and
DNA vaccination. Although more than 30 deﬁned vaccines have been studied in laboratory
models no human formulation has been licensed so far; however three second-generation
canine vaccines have already been registered. As expected for a zoonotic disease, the
recent preventive vaccination of dogs in Brazil has led to a reduction in the incidence of
canine and human disease. The recent identiﬁcation of several Leishmania proteins with
T-cell epitopes anticipates development of a multiprotein vaccine that will be capable of
protecting both humans and dogs against VL.
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WHY IS LEISHMANIOSIS IMPORTANT TO HUMAN AND
VETERINARY MEDICINE?
Human leishmaniasis, caused by several species of Leishmania,
comprises a group of diseases which are mostly zoonotic. These
include visceral leishmaniasis (VL) and the cutaneous and muco-
cutaneous forms (CL). This group of infections is the third
most important vector-borne disease after malaria and lymphatic
ﬁlariasis (Solano-Gallego et al., 2009).
According to WHO, leishmaniasis is considered to be endemic
in 88 countries, with more than 350 million people at risk. The
estimated incidence is 2 million new cases per year, 0.5 million
of VL, and 1.5 million of CL [World Heath Organization (WHO,
2011)]. Without prompt appropriate treatment as many as 95%
of kala-azar patients die resulting in at least 50,000 deaths per year
worldwide (Chappuis et al., 2007). Ninety percent of the human
cases of VL are notiﬁed in Bangladesh, India, Nepal, Sudan, and
Brazil, 95%of the cases of humanCLare reported inBolivia,Brazil,
and Peru (mucocutaneous leishmaniasis), and 90% of cutaneous
leishmaniasis cases occur in Afghanistan, Brazil, Iran, Peru, Saudi
Arabia, and Syria (WHO, 2011). These statistics and epidemio-
logical data however, are certainly an underestimation since they
were ﬁrst published byWHO in 1993 and have remained unaltered
until now (WHO, 2011). Over the last two decades however many
factors determined the increase in the incidence of human VL.
Among them we can consider the geographical spread of VL in
Europe, Africa, America, and Asia (Romero and Boelaert, 2010;
Palatnik-de-Sousa and Day, 2011) caused by human migration
carrying infected dogs to areas where the speciﬁc insect vector
was already present (Maguill, 1995); the expansion of the phle-
botomine habitats due global warming (Witt et al., 2009); the
increase in dog cases with a travel history (Duprey et al., 2006);
the urbanization of the disease after deforestation (Harhay et al.,
2011); and the frequent coinfection in HIV-positive individuals
(Evans and Kedzierski, 2012).
Visceral leishmaniasis is a chronic and frequently lethal disease
caused by protozoan parasites of the Leishmania donovani com-
plex, order Kinetoplastida. The etiological agents are: L. donovani
in India and Central Africa and Leishmania infantum in the Amer-
icas, the Middle East, Central Asia, China, and the Mediterranean.
The human disease is lethal if not treated soon after the onset
of clinicopathological abnormalities that include: malaise, ane-
mia, cachexia, hypergammaglobulinemia, hepato-splenomegaly,
and progressive suppression of the cellular immune response.
The L. donovani complex species are intracellular parasites of
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macrophages of lymphoid organs such as the spleen, lymph nodes,
bone marrow, and liver. Their biological cycle alternates between
the amastigote form in the vertebrate host and the promastigote
form in the gut of the sand-ﬂy vector (WHO, 2011).
Considering the presence or absence of animal reservoirs
for Leishmania, two basic types of epidemiological cycles are
noted: zoonotic (ZVL) or anthroponotic (AVL; reviewed by
Palatnik-de-Sousa and Day, 2011).
AVL in India and Central Africa is caused by L. donovani
and involves a severe parasitism of the blood and skin and an
anthropophilic vector, making man the reservoir of the disease. In
contrast, ZVL with dogs as the reservoir hosts is usually associated
with L. infantum and is found in the Americas, the Middle East,
Central Asia, China, and the Mediterranean. Sandﬂies become
infected mostly by feeding on the skin of canids and humans are
the ﬁnal host of the parasites.
“One Health” proposes the uniﬁcation of medical and veteri-
nary sciences with the establishment of collaborative ventures in
clinical care, surveillance and control of cross-species disease, edu-
cation, and research into disease pathogenesis, diagnosis, therapy,
and vaccination. The concept encompasses the humanpopulation,
domestic animals and wildlife, and the impact that environmen-
tal changes (“environmental health”) such as global warming will
have on these populations. “One Health” proposes taking a holis-
tic view of the previously distinct disciplines of human medicine,
veterinary medicine, environmental science, and wildlife conser-
vation (Palatnik-de-Sousa and Day, 2011). ZVL is a disease that
epitomizes perfectly the need for a One Health approach since
the disease occurs in both, dogs and humans, with similar symp-
toms, clinical outcome, and commitment of the integrity of the
T-cell related immunity (Reis et al., 2010; Palatnik-de-Sousa and
Day, 2011). Tools for control of canine ZVL will have impact on
the reduction of the human incidence of ZVL (Palatnik-de-Sousa
et al., 2009).
The present review examines the current state-of-the-art of
the development and use of vaccines for canine leishmaniasis as
the most worthy cost–beneﬁt tool for the control and prevention
of ZVL.
LEISHMANIASIS IN CANIDS
A broad range of immune responses and clinical manifestations
have been described in canine ZVL (Baneth et al., 2008; Solano-
Gallego et al., 2011). These aspects have been thoroughly revised by
the LeishVet group in order to establish guidelines for canine ZVL
management (Solano-Gallego et al., 2011). Infection in dogs may
be subclinical or manifested as a self-limiting disease, or a severe,
and sometimes, even if treated, fatal illness (Solano-Gallego et al.,
2011). Subclinical infection is not necessarily permanent and fac-
tors such as immunosuppression or concomitant diseases could
break the equilibrium and lead to the progression of the clin-
ical disease in dogs (Baneth et al., 2008; Solano-Gallego et al.,
2009) as has been observed in humans coinfected with the human
immunodeﬁciency virus and Leishmania (Alvar et al., 2008). Of
note, the infection of cats by L. infantum was recently reported
(Maia and Campino, 2011; Vides et al., 2011) and a correlation
between cat infection by the feline immunodeﬁciency virus (FIV)
and leishmaniasis was also described (Vides et al., 2011).
Since the proportion of clinical cases of canine ZVL is lower
than that of the subclinical cases, and a positive correlation
between clinical status and infectiosity to the sand-ﬂy has been
established (Travi et al., 2001), when high vector sand-ﬂy and
canine–host densities are present, the infection spreads quickly
and extensively among the dog population (Quinnell et al., 1997,
2003; Oliva et al., 2006).
Several predisposing factors for the development of the disease
have been described including breed, age, and genetic background.
As for breed susceptibility, the German shepherd dog (Ranque
et al., 1977;Abranches et al., 1991) togetherwith the boxer (Ranque
et al., 1977) and doberman (Abranches et al., 1991; Sideris et al.,
1996) breeds appear to be predisposed to infection in France, Por-
tugal, andGreece. In contrast, inGreece dogs of the collie breed are
rarely infected (Sideris et al., 1996) and there is a well-known resis-
tance in Ibizan hounds in Spain (Solano-Gallego et al., 2000). In
Brazil however, themost affected breeds are the long-coated cocker
spaniel (26.9%) and the short-coated boxer (24.6%; França-Silva
et al., 2003),while in Italy no breed-related predisposition has been
reported (Pozio et al., 1981).
Age seems to be an important factor (Pozio et al., 1981; Sideris
et al., 1996). The distribution of the disease is considered bimodal
in Europe, with the highest prevalence reported in dogs younger
than 3 years and older than 8 years (Abranches et al., 1991; Car-
doso et al., 2004). This was not supported however by a Brazil-
ian study of 33,937 dogs (França-Silva et al., 2003). No speciﬁc
canine gender predisposition has been described for ZVL in vari-
ous endemic countries (Pozio et al., 1981; Abranches et al., 1991;
Sideris et al., 1996; Antônio et al., 2007); however, in France a
greater prevalence of ZVL was found among male dogs (Lanotte
et al., 1975) and in an endemic area of Brazil high rates of seropos-
itivity were also found amongmale animals (Mouta-Confort et al.,
2010).
ZVL in dogs is a systemic disease that may potentially involve
any organ, tissue, or body ﬂuid and is manifested by non-speciﬁc
clinical signs. The most common clinical manifestations and clini-
copathological abnormalities found in canine ZVL are thoroughly
described by the LeishVet group (Solano-Gallego et al., 2011).
Skin lesions are the most frequent manifestation among them and
may be seen along with other clinical signs or clinicopathological
abnormalities. Clinical manifestations include generalized lym-
phadenopathy, loss of weight, altered appetite, lethargy, mucous
membrane pallor, splenomegaly, polyuria and polydipsia, fever,
vomiting and diarrhea, dermatitis, onychogryphosis, blepharitis,
conjunctivitis, keratoconjunctivitis, uveitis, oral, genital, and/or
nasal mucocutaneous and mucosal lesions, epistaxis, vascular,
and neurological disorders (Solano-Gallego et al., 2011). Among
the main laboratory abnormalities, hypergammaglobulinemia,
hypoalbuminemia,decreased albumin/globulin ratio, anemia, leu-
copenia, thrombocytopenia, proteinuria, renal azotemia, and ele-
vated liver enzyme activities were described (Solano-Gallego et al.,
2011).
Renal disease may be the sole clinical manifestation of canine
ZVL and it can progress from mild proteinuria to the nephrotic
syndrome or to an end stage renal disease. Chronic renal failure is
a severe result of disease progression and the main cause of mor-
tality due to ZVL. However, the variable and non-speciﬁc clinical
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signs make the list of differential diagnoses wide and extensive
(Solano-Gallego et al., 2011).
There have been numerous reports of the cutaneous pathol-
ogy in the chronic stages of canine leishmaniosis and in some
of these the presence of intracellular amastigotes within the
macrophages forming the granulomatous dermatitis has been
highlighted immunohistochemically (Koutinas et al., 1993; Maia
and Campino, 2008; Day, 2011). Immunohistochemical studies
have also shown that in the relatively milder clinical lesions of
exfoliative dermatitis there is a low parasite burden, associated
with enhanced expression of class II molecules of the major his-
tocompatibility complex (MHC) by keratinocytes and a dermal
T-cell inﬁltrate dominated by CD8+ cells over the CD4+ T helper
(Th) subpopulation. In contrast,with the increasing severity of the
cutaneous disease (the nodular form) there is reduced expression
of class II molecules of the MHC by epidermal Langerhans cells
and keratinocytes and fewer inﬁltrating T-lymphocytes (Papado-
giannakis et al., 2005; Saridomichelakis, 2009). The lymph nodes
of asymptomatic Leishmania-infected dogs are hyperplastic, but
when the disease becomes symptomatic there is more often an
atrophy of the lymph node cortex (Giunchetti et al., 2008a). The
systemic pathological changes of canine ZVL have been reviewed
recently (Day, 2011).
CELLULAR IMMUNE RESPONSES IN CANINE ZVL
Susceptibility and resistance to the development of canine leish-
maniasis depends on the immune response elicited in the dog after
natural infection. According to Reis et al. (2010), the evaluation
of different factors like parasite burden, humoral response, cell-
mediated immunity (CMI), or cytokine expression, have a predic-
tive value for the progress of the infection and should, therefore,
be taken into account as hallmarks of resistance and susceptibility
to canine leishmaniasis (Reis et al., 2010). Increased levels of para-
meters like parasite load, IL-10, and TGF-β expression, Leishma-
nia-speciﬁc cell immunodepression or Leishmania-speciﬁc-IgG,
IgM, IgA, and IgE serum antibodies are related to the clinical dis-
ease progression (Reis et al., 2010). By contrast, increased levels
of parameters such as PBMCs proliferation after leishmanial anti-
gen stimulation, IFN-γ and TNF-α expression, proliferation of
CD4+,CD8+, andB-cell subsets, or a positive leishmanin skin test
(LST) are related to resistance (Reis et al., 2010). The different bal-
ance established between the factors involved in the host immune
response are reﬂected in the spectrum of clinical forms that can
be observed in naturally infected dogs, ranging from symptomatic
severe canine leishmaniasis to asymptomatic animals (Reis et al.,
2010). In agreement with that, the increase of IFN-γ in cured cases
was also described (Manna et al., 2008).
Other studies however, point out that the expression of IFN-
γ was similar in symptomatic and asymptomatic dogs (Quinnell
et al., 2001; Corrêa et al., 2007; Lage et al., 2007) or even higher
and associated with the increase of parasite load and clinical status
in susceptible dogs (Sanchez-Robert et al., 2008; Travi et al., 2009).
Supporting these ﬁndings an initial asymptomatic phase, followed
by a short-term production of Th1 type cytokines before the
appearance of clinical signs (Santos-Gomes et al., 2002) or an ini-
tial elevation in IL-4 followed by an increase in the Th1-associated
IFN-γ were described (Strauss-Ayali et al., 2007). Different from
what Reis et al. (2010) stated, the high variability of the basal
levels of these cytokines could not indicate the prognosis of
the subsequent response against infection (Sanchez-Robert et al.,
2008).
On the other hand, spleen cells from infected dogs showed a
predominant expression of IL-10 that was positively correlated
with parasitic load and clinical status severity (Pinelli et al., 1999;
Chamizo et al., 2005; Lage et al., 2007; Alves et al., 2009).
A spectrum of innate and acquired immune responses to L.
infantum infection is mounted by the canine–host (Baneth et al.,
2008; Reis et al., 2010). Protective immunity to canine ZVL is T-
cell-mediated and susceptibility to the overt disease is associated
with a marked non-protective humoral immune response and a
depressed CMI (Pinelli et al., 1994; Barbieri, 2006; Baneth et al.,
2008).
When a cellular immune response is present, dogs appear
asymptomatic and IDR (intradermal response to leishmanial anti-
gen) positive, with higher levels of IL-2 and TNF-α and a mixed
TH1/TH2 response involving TH1 evolution mediated primarily
by IL-12, IL-18, and IFN-? (Chamizo et al., 2005). In asympto-
matic dogs, macrophages are capable of killing amastigotes via
the nitric oxide route (Vouldoukis et al., 1996), and there is an
increase in CD8+ T-cells in peripheral lymphocytes, and MHC
class II molecules and the receptors CD45RA and CD45RB are
also expressed (Reis et al., 2006a). In contrast, symptomatic dogs
show a failed cellular response, with no IDR or lymphocyte pro-
liferation and the following additional characteristics: decrease
in CD14+ monocytes; decrease in CD8+ (Reis et al., 2006a),
CD4+ T-lymphocytes, and CD21+ B lymphocytes, either Leish-
mania-speciﬁc or not; antibody increase; deﬁciency of the co-
stimulatory response; decrease of IFN-γ; and reduced expression
of MHC class II molecules, which renders the animal more sus-
ceptible (Bourdoiseau et al., 1997; Moreno et al., 1999; Pinelli
et al., 1999; Guarga et al., 2000, 2002; Borja-Cabrera et al.,
2004).
The majority of infected dogs are likely to develop positive
speciﬁc CMI expressed as proliferation of lymphocytes stimu-
lated in vitro by Leishmania antigen or in vivo by a positive skin
test early in infection. However, as the disease progresses in sus-
ceptible dogs, these responses diminish. Blood parasite load and
Leishmania-speciﬁc CMI were shown to be inversely correlated
during a longitudinal follow-up of experimentally infected dogs
(Rodríguez-Cortés et al., 2007a). CMI unresponsiveness in pro-
gressive disease has been postulated to be due to the decrease in
peripheral CD4+ T-cell numbers or the decreasing expression of
co-stimulatory molecules such as B7 (Pinelli et al., 1999; Guarga
et al., 2000; Alvar et al., 2004; Barbieri, 2006).
It is now widely accepted that protective immunity against
Leishmania parasites is mediated by CD4+ T helper1 (Th1) cel-
lular responses (Strauss-Ayali et al., 2007) and that the decrease
in CD4+ T-cell numbers is highly correlated with parasitism and
with the infectious condition to the sand-ﬂy vector (Guarga et al.,
2000, 2002; Travi et al., 2001). Similar to the situation in human
VL patients, symptomatic disease in dogs is correlated with a“sup-
pressive”pattern of T-cell responses,with a dominant role of IL-10
in ongoing, non-protective immune responses (Nylen and Sacks,
2007; Alves et al., 2009; Carrillo and Moreno, 2009).
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HUMORAL IMMUNE RESPONSE IN CANINE ZVL
Canine leishmaniosis is frequently associated with a marked
humoral response, which is not protective and signiﬁes fail-
ure to control the infection. The levels of Leishmania-speciﬁc
immunoglobulins detected in symptomatic dogs are greater than
those detected in infected but asymptomatic dogs, and a marked
association was found between these levels, the clinical status, and
the tissue parasite density (Reis et al., 2006b).
Canine ZVL shows very similar characteristics to the human
disease (Palatnik-de-Sousa, 2008; Kaye and Aebischer, 2011). IgA,
IgE, and IgM responses have been shown to be markers of the dis-
ease (Almeida et al., 2005; Iniesta et al., 2005; Rodríguez-Cortés
et al., 2007b). An IgG antibody increase is also observed and
correlated with symptomatology (Keenan et al., 1984; Courtenay
et al., 2002; Nogueira et al., 2005) with the IgG1 subtype associ-
ated to susceptibility and severe disease and the IgG2 increased
in natural resistant or vaccinated dogs (Deplazes et al., 1995;
Bourdoiseau et al., 1997; Nieto et al., 1999; Solano-Gallego et al.,
2001; Santana et al., 2002; Mendes et al., 2003; Quinnell et al.,
2003; Ramiro et al., 2003; Borja-Cabrera et al., 2004; Fujiwara
et al., 2005; Rafati et al., 2005; Santos et al., 2007). The IgG2
subtype also predominates in the canine response to vaccina-
tion against other infections (Ma et al., 1995; Chabalgoity et al.,
2001). However, conﬂicting results have been reported, with the
predominance of the IgG2 subtype observed in symptomatic dogs
(Vercammen et al., 2002; Fernandez-Perez et al., 2003; Iniesta et al.,
2005; Reis et al., 2006b; Day, 2007). Since all investigations used
the same manufactured anti-dog conjugates, the discrepancy in
results could be due to difference in titration of the conjugates
(Mendes et al., 2003). On the other hand, while most studies
defending the IgG2 predominance deal with vaccinated dogs and
used puriﬁed (Mendes et al., 2003; Borja-Cabrera et al., 2004;
Santos et al., 2007) or recombinant vaccine antigens for diagno-
sis (Nieto et al., 1999; Santana et al., 2002; Ramiro et al., 2003;
Fujiwara et al., 2005; Rafati et al., 2005), the investigations that
associate IgG2 to symptomatology, and disease used promastigote
crude antigens (Vercammen et al., 2002; Fernandez-Perez et al.,
2003; Rafati et al., 2005; Reis et al., 2006b). The differential afﬁn-
ity of the antigen could be another factor of the discrepancy.
In dogs vaccinated with the CPa and CPb cysteine proteinases
(Rafati et al., 2005) higher IgG2 than IgG1 titers were detected
against the recombinant antigens but not against the L. infantum
lysate. While the recombinant antigen interacts with a deﬁned
fraction of sera antibodies, the total lysate interacts with the whole
plethora of antibodies directed against the total parasite (Palatnik-
de-Sousa, 2008). Another factor of discrepancy could be the use
of different batches of the polyclonal anti-IgG2 and anti IgG1
antisera, which show low repeatability These difﬁculties stimu-
lated Dr. M. J. Day to obtain dog monoclonal antibodies that
recognize four different IgG subfractions (Day, 2007; Marcondes
et al., 2011). Unfortunately, these antibodies are not commercially
available.
WHAT ARE THE SUITABLE ACTIONS FOR THE CONTROL OF
CANINE ZVL
For the control of leishmaniasis,WHO recommends: (1) the treat-
ment of human patients, (2) the culling of seropositive infected
dogs, and (3) the insecticidal treatment of human homes (Tesh,
1995; WHO, 2011).
Human cases should be diagnosed and treated as swiftly as
possible (Ministério da Saúde, 2006). However in the case of ZVL
humans are not the main reservoir of the infection.
A second preventive tool for ZVL in Brazil is control of the
canine reservoir by removal and humane destruction of the Leish-
mania-seropositive and/or infected dogs and elimination of their
carcasses (Ministério da Saúde, 2006).Althoughmany studies sup-
port the efﬁcacy of the culling control campaign (Magalhães et al.,
1980; Ashford et al., 1993; Braga et al., 1998; Jerónimo et al., 2000;
de Oliveira and de Araújo, 2003; Costa et al., 2007; Nunes et al.,
2010) a few investigations showopposite results (Dietze et al., 1997;
Paranhos-Silva et al., 1998; Moreira et al., 2004; De Souza et al.,
2008; Nunes et al., 2010) and this strategy is frequently debated
(Quinnell and Courtenay, 2009; Romero and Boelaert, 2010). At
present, the removal of infected dogs is undertaken systemati-
cally only in Brazil (Palatnik-de-Sousa et al., 2001; Romero and
Boelaert, 2010) and eventually in other South American coun-
tries (Romero and Boelaert, 2010) and China (Wang et al., 2010)
and not regularly performed in the Mediterranean basin where
chemotherapy treatment is preferred however they do not prevent
relapses (Baneth and Shaw, 2002).
A third tool for control is the monitoring of the sand-ﬂy
vector in human residences and peri-domestically by spraying
with pyrethroids. The use of deltamethrin-impregnated collars in
dogs and of nets (with or without insecticides) in human homes
and dog kennels is also recommended. A decrease in the preva-
lence of canine ZVL was observed after 65% permethrin spot-on
treatment of dogs (Giffoni et al., 2002) and a signiﬁcant reduc-
tion of anti-Leishmania antibody titers in dogs was observed in
dogs using insecticide-impregnated collars (Killick-Kendrick et al.,
1997;Maroli et al., 2001; Reithinger et al., 2004) and spot-on repel-
lents (Miró et al., 2007; Ferroglio et al., 2008; Thomas et al., 2008).
In southern Europe the use of deltamethrin-impregnated dog col-
lars (Killick-Kendrick et al., 1997; Maroli et al., 2001) is preferred
by many dog owners. Alternatively, there is substantial evidence
for the efﬁcacy of spot-on repellents containing imidacloprid, per-
methrin, pyriprole, metaﬂumizone, or amitraz (Miró et al., 2007;
Ferroglio et al., 2008; Thomas et al., 2008). In the Mediterranean
region, human and canine cases of ZVL are treated with antipar-
asitic drugs. In Europe, individual measures to protect dogs from
sand-ﬂy bites using insecticides are commonly practiced, but no
public health surveillance and control interventions such as those
applied in Brazil are in place (Palatnik-de-Sousa et al., 2001).
Themathematicalmodel described byDye condemned the epi-
demiological ZVL control campaign, considering it non-efﬁcient
and indeed, at low rates of canine seropositivity, no impact on the
human incidence of the disease was observed (Dye, 1996; Palatnik-
de-Sousa et al., 2004). However, at higher rates of canine seropos-
itivity, corresponding to more sensitive diagnostic methods, the
number of infectious dogs declined interrupting the transmission
and the spread of epidemics (Palatnik-de-Sousa et al., 2004). The
low acceptance of culling of companion animals by their own-
ers, the ethical dilemmas of veterinarians and humane reasons
demand the development of alternative preventive tools. Mathe-
matical modeling suggests that vector control and vaccination of
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dogs and/or humans would be more efﬁcacious than dog culling
(Dye, 1996).
VACCINES FOR HUMAN LEISHMANIASIS
In spite of an estimated 500,000 cases andmore than 50,000 deaths
annually (WHO, 2011), human VL has been considered an unat-
tractive vaccine target for industry, being primarily a disease of the
poor. Human VL however, ranks second only to malaria for mor-
tality and fourth for morbidity amongst tropical parasitic diseases
(Mathers et al., 2007).
Although the century-old practice of leishmanization, the
deliberate infection of naive people with virulent Leishmania
major, is defended by some authors for vaccination against tegu-
mentary leishmaniasis (Khamesipour et al., 2006), the develop-
ment of lesions resistant to treatment makes this practice unrec-
ommendable. Furthermore, while ﬁrst generation vaccines of
whole killed parasite vaccines have been developed and tested
against CL and VL their average clinical efﬁcacy was considered
to be low (54%; reviewed in Palatnik-de-Sousa, 2008). Indeed,
the only ﬁeld trial against human VL was performed in Sudan
(Khalil et al., 2000), with an autoclaved L. major vaccine with
BCG and achieved 43.3% of vaccine efﬁcacy (VE= incidence in
non-vaccinated individuals – incidence in vaccinated individu-
als/incidence in non-vaccinated individuals× 100), only among
LST converters,which is impressive considering the highmortality
and virulence of kala-azar in that area. The safety of this prepa-
ration on children was also assayed (Khalil et al., 2006). These
data however are contested by a recent metanalysis (Noazin et al.,
2009).
Only a single product (Leish-111f), a fusion protein of three
relatively conserved L. major proteins (thiol-speciﬁc antioxidant,
stress inducible protein 1, and elongation initiation factor) formu-
lated with MPL-SE is entering phase II clinical testing in humans,
including human VL as a therapeutic vaccine (Coler and Reed,
2005; Nascimento et al., 2010) but there is no human vaccine
licensed for prophylaxis against VL.
FIELD ASSAYS OF VACCINES AND LICENSED VACCINES FOR
CANINE LEISHMANIASIS
Many Leishmania antigens have been identiﬁed as potential vac-
cine candidates against canine ZVL (reviewed by Palatnik-de-
Sousa, 2008), but very few have been tested in ﬁeld assays.
The ﬁrst generation vaccines developed for humans were also
tested against canine ZVL. In an initial comparison of vaccine
formulations, with no challenge, Lasri et al. (1999) demonstrated
that dogs vaccinated with autoclaved L. major promastigote lysate
(ALM) and BCG showed an in vitro lymphocyte proliferative
response, while dogs immunizedwithALMand saponin expressed
a main humoral antibody response against L. infantum. Mayrink
and co-workers, using a Leishmania braziliensis lysate and BCG
vaccine, in a formulation related to the Leishvacin, previously
shown to be about 50% protective against tegumentary leishma-
niasis in humans (Antunes et al., 1986), obtained 90% protection
against experimental canine kala-azar in the kennel (Mayrink et al.,
1996) but failed to detect any signiﬁcant difference between vac-
cines and placebos in a well designed ﬁeld Phase III assay (Genaro
et al., 1996; Table 1). The 90% protection in the kennel assay was
related to the absence of the parasite in bone marrow cultures of 9
of the 10 vaccinated dogs that were challenged with only 106 cul-
tured promastigotes of Leishmania chagasi (Mayrink et al., 1996).
The difference between the artiﬁcial and the natural challenge in
this case could account for the failure of the vaccine in the ﬁeld
assay. In Iran, on the other hand the use of Aluminum hydrox-
ide precipitated L. major vaccine plus BCG resulted in 69.3% of
vaccine efﬁcacy against the natural infection by L. infantum in
Iran (Mohebali et al., 2004; Table 1). The incidence rate was 3.7%
(6/162) in vaccinated dogs and 12.0% (17/141) in control dogs.
In the ﬁrst Phase III trial with a second-generation dog vac-
cine, Dunan et al., using a L. infantum semi-puriﬁed lyophilized
protein preparation (94–67 kDa), paradoxically achieved, a signif-
icantly higher rate of infection in vaccinated than in control dogs.
This vaccine then, while effective in murine models, developed no
protection against canine kala-azar in the ﬁeld (Dunan et al., 1989;
Table 1).
Two dog vaccines achieved successful results in Phase III tri-
als: the fucose–mannose ligand (FML)–saponin vaccine (Leish-
mune®; da Silva et al., 2001; Borja-Cabrera et al., 2002, 2010;
Palatnik-de-Sousa et al., 2008) composed of the antigen of L.
donovani promastigotes, named FML (Palatnik et al., 1989) and
the QS21 and deacylated saponins of Quillaja saponaria (Oliveira-
Freitas et al., 2006; Table 1). The FML was antigenic for human
(Palatnik-de-Sousa et al., 1995) and dogs (Borja-Cabrera et al.,
1999) and Leishmune® was immunogenic, immunoprophylactic,
and immunotherapeutic in mice and hamsters and ﬁeld trials for
dogs (Palatnik-de-Sousa et al., 1994; Santos et al., 2002, 2003, 2007;
Borja-Cabrera et al., 2004, 2008, 2010). In the ﬁrst Phase III assay,
four obits and six symptomatic cases among 30 surviving placebo
treated dogs (33%)were detected and conﬁrmed by parasite analy-
sis and PCR. No obits were detected among vaccines and infection
was conﬁrmed in 3/36 oligosymptomatic dogs (8.33%), making
92% protection, and 76% vaccine efﬁcacy (da Silva et al., 2001).
In the second assay, the infective pressure was higher and 2 years
after vaccination, obits were detected in 8/33 (25%) of the placebo
treated and 1/20 (5%) of the vaccinated dogs, making 95% pro-
tective effect and 80% vaccine efﬁcacy. This protection lasted for
at least 3.5 years and was concomitant with the reduction of the
human incidence of the disease in the area (Borja-Cabrera et al.,
2002). Noteworthy, the VE values for the FML–saponin vaccine
revealed protection against severe diseases and obits due to canine
ZVL (Palatnik-de-Sousa et al., 2008).
The FML-vaccine was considered a second-generation vaccine
candidate and participated in the fourth Meeting on Second-
Generation-Leishmania vaccines held in Mérida in May 2001
(Dumonteil et al., 2001). In 2003, the FML–saponin vaccine was
licensed for prophylaxis against canine ZVL in Brazil under the
name of Leishmune®, and has been used in Brazil since 2004 and
it obtained its deﬁnitive license in October, 2011.
The vaccine was considered safe and was well tolerated (Parra
et al., 2007; Table 1). After 2 years of vaccination of a cohort of
550 Leishmune® vaccinated exposed dogs, only 1% of the ani-
mals died of ZVL and 1.2% were symptomatic. Simultaneously,
39% of deaths and 20.6% of symptomatic cases were detected
among untreated exposed control animals (p< 0.005; Borja-
Cabrera et al., 2008). The Leishmune® vaccine is prophylactic
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Table 1 | Canine vaccines for visceral leishmaniasis assayed in field trials.
Vaccine Composition Licensed* VE (%)** Results obtained
Leishvacin L. braziliensis
lysate+BCG
− − Protective in kennel assay but failed in Phase III assay in Brazil
ALM Aluminum
hydroxide-L. major
− 69.3 Protective against natural infection by L. infantum in Iran
Lyophilized
protein
preparation
L. infantum
semi-puriﬁed
proteins (94–67 kDa)
− − Protective in mice assays but not in ﬁeld trial in France
Leishmune® L. donovani FML
antigen and QS21
and deacylated
saponins of Quillaja
saponaria
+ 76–80 Immunogenic, immunoprophylactic, and immunotherapeutic in mice and hamsters
Long-lasting protection against infection, severe disease, and deaths of ZVL in dog
ﬁeld trials in Brazil
Safe and well tolerated
Vaccinated dogs do not expose parasites and are negative in xenodiagnosis
The generated dog antibodies block the transmission of the disease by sand ﬂies
With double saponin concentration is therapeutic against naturally or experimentally
acquired ZVL. In immunochemotherapy promotes the sterile cure
Leishmune® enhances the levels of IFN-γ, NO, and anti-L. chagasi IgG2, the early and
persistent activation of neutrophils and monocytes
Leishmune® increases the CD8+ T-cells expressing IFN-γ and sustain or increases
the proportions of CD4+ and CD21-B lymphocytes
Leishmune® vaccination does not interfere in epidemiological serological control tests
A decrease in human and canine incidence and in canine seroprevalence of ZVL was
observed after dog vaccination in two Brazilian towns
LiESAP 54 kDa excreted
protein of L.
infantum +MDP
− 92% Long-lasting protection against, infection but not against deaths or severe disease by
ZVL, in a ﬁeld assay performed in France at a lower infective pressure endemic region
Vaccinated dogs showed a signiﬁcant leishmanicidal effect of macrophages due to
an IFN-γ dependent activation; a NO-mediated apoptosis of intracellular amastigotes,
a strong and long-lasting cell-mediated immunity revealed by positive IDR, an anti-
leishmanial activity of monocytes, and by the in vitro activities of the anti-LiESAp
antibodies
A similar antigen to LiESAp+QA21 saponin was licensed in Europe in 2011 with
undisclosed results of ﬁeld assays
*For prophylaxis against canine visceral leishmaniasis.
**VE, vaccine efﬁcacy in Phase III trials.
against canine ZVL VL, protects 98% of vaccinated dogs (Borja-
Cabrera et al., 2008), and reduces the parasite burden accessible
for transmission back to sand ﬂies, as disclosed by their negative
results of PCR for Leishmania DNA in blood and lymph nodes and
negative immunohistochemistry reactions in skin (Nogueira et al.,
2005). The generated antibodies block the transmission of the dis-
ease by sandﬂies in the ﬁeld (Saraiva et al., 2006; Palatnik-de-Sousa
et al., 2008). Indeed, while sand ﬂies fed upon pre-immune sera
showedhigher percent of infection andnumber of parasites/insect,
giving a high infection index, sand ﬂies fed upon Leishmune® sera
(mainly IgG2 anti-FML antibodies) showed a 74.3% reduction
in infection; (Saraiva et al., 2006). On the other hand, compared
to the respective pre-immune fed controls, the sand ﬂies fed on
sera of infected animals (IgG1 predominant antibodies) showed,
a pronounced enhancement of infection (331.9%; Palatnik-de-
Sousa et al., 2008). Xenodiagnosis using Lutzomyia longipalpis
disclose that 2/9 naturally infected dogs, infected phlebotomies,
while 0/19 Leishmune® vaccinated dogs did not. The two infected
dogs showing positive xenodiagnosis were the most symptomatic
(more than three clinical signs) among the nine tested, while the
other seven were asymptomatic or oligosymptomatic (Palatnik-
de-Sousa et al., 2008; de Amorim et al., 2010). The anti-FML
antibody response induced by Leishmune® is mainly of the IgG2
subtype (Mendes et al., 2003). A total of 150,000 healthy dogs were
vaccinated in Brazil up to October 2011. We also observed that
Leishmune® formulated with double saponin adjuvant concentra-
tion has a therapeutic effect against naturally (Borja-Cabrera et al.,
2004) or experimentally acquired ZVL (Santos et al., 2007). While
immunotherapy with the saponin-enriched Leishmune® reduces
the symptomatology, the rate of obits and the parasite load in
lymph nodes, immunochemotherapy with Leishmune®,Allopuri-
nol, and Amphotericin B promotes the sterile cure, turning to
negative the PCR reactions for Leishmania DNA (Borja-Cabrera
et al., 2010).
Leishmune® induced an immunological pattern characterized
by enhanced levels of IFN-γ, NO, and anti-L. chagasi IgG2 (Araújo
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et al., 2009), the early and persistent activation of neutrophils
and monocytes, and increased the CD8+ T-cells expressing IFN-γ
(Araújo et al., 2008; Table 1). This increase of CD8+ T-cells is
expected for the QS21 saponin adjuvant of Leishmune® (Oliveira-
Freitas et al., 2006) and itwas also described in the immunotherapy
assays against naturally (Borja-Cabrera et al., 2004) and exper-
imentally acquired ZVL (Santos et al., 2007). Leishmune® also
induced early phenotypic changes in neutrophils (increase in
MHCII+ and decrease inCD32+ andCD18+ activationmarkers)
and monocytes, CD8+ T-cell activation, and a selective pro-
inﬂammatory pattern (IFN-γ/NO; Araújo et al., 2011). Other
studies also revealed the sustained or increased proportions of
CD4+ andCD21-B lymphocytes and the increased proportions of
CD8+ T-cells (Borja-Cabrera et al., 2004, 2010; Santos et al., 2007)
and the diminished CD4+/CD25+ T-cell counts and increased
IFN-γ levels in dogs vaccinated with Leishmune® (de Lima et al.,
2010). Similar to the situation of human VL patients, the sympto-
matic disease in dogs is correlated with a “suppressive” pattern of
T-cell responses, with a dominant role for IL-10 in ongoing, non-
protective immune responses (Nylen and Sacks, 2007; Carrillo and
Moreno, 2009). In view of this similarity between human and
canine VL, the fact that Leishmune® has shown promise as a ther-
apeutic vaccine in ZVL is encouraging. The therapeutic efﬁcacy in
ZVL of Leish-110f, which induces mainly B-cell and CD4+ T-cell
responses, was indistinguishable from the effect of the MPL-SE
adjuvants alone (Miret et al., 2008). This may suggest that a thera-
peutic vaccine against humanVL should, akin to canine ZVL, aim
to induce both CD4+ and CD8+ T-cells (Kaye and Aebischer,
2011).
Since canine ZVL in Brazil is epidemiologically controlled by
serological enquire, and Leishmune® was designed to induce a
strong humoral response against the FML antigen, to facilitate the
monitoring during ﬁeld assays, there was a concern that vacci-
nated dogs could not be differentiated serologically from infected
dogs (Marcondes et al., 2011). The predominance of IgG2 anti-
bodies to FML, on the other hand, was proposed to be a tool for
differentiation (Mendes et al., 2003). The results obtained from
the control campaign disclosed however that there was no reason
for concern since in the ﬁeld, dogs vaccinated with Leishmune®
did not become seroreactive in the ofﬁcial test used by the enquire
(Palatnik-de-Sousa et al., 2009; Table 1). In the epidemic area of
Campo Grande, Brazil, the serological control campaign evalu-
ated 110,000 dogs, 5,860 of which were Leishmune® uninfected
vaccines. Only 1.3% of positivity (76 among 5,860) was detected.
These seropositive dogs were seronegative for the L. chagasi HSP
recombinant antigen and showed no parasite evidence in bone
marrow and lymph nodes (Palatnik-de-Sousa et al., 2009).
A possible additive effect of Leishmune® vaccination over dog
culling, on the decrease of the incidence of canine and human
ZVL was studied in two Brazilian endemic areas, from 2004 to
2006 (Palatnik-de-Sousa et al., 2009; Table 1). In Araçatuba, a
decline of 25% was seen in the incidence of ZVL in dogs with a
61% decline in human cases (36–14 cases), indicating the addi-
tive effect of Leishmune® vaccination over regular dog culling. In
Belo Horizonte, where 8.1% (12,113/149,470) of the dogs were
vaccinated up to 2006, the districts that had had greater vaccine
coverage (85.7% of the doses) exhibited declined or sustained
levels of canine and human cases of ZVL, while those with less
vaccine coverage (14.3% of the doses), showed rising curves of
canine and human cases of the disease. In the districts with higher
vaccination levels, human cases declined by 36.5% falling from
2004 to 2006 outside of the 95% conﬁdence interval (CI95%) of
the less vaccinated districts (CI95% 2.23–21.11), which showed
an average increase of 11.67%. From 1999 to 2006, the increase
of canine seroprevalence and of human cases of the disease in all
districts were signiﬁcantly correlated (p = 0.001), conﬁrming the
importance of the dog as the infectious reservoir of the disease.
The decrease in dog culling (−p = 0.007) and human incidence
(−p = 0.043) were signiﬁcantly correlated with the increase in the
number of vaccinated animals, indicating the prophylactic impact
of Leishmune® vaccination on the decrease of the proportions of
infectious dog and human populations, and so indirectly indicat-
ing a decrease in the number of dogs sacriﬁced (Palatnik-de-Sousa
et al., 2009).
The mathematical model for control of leishmaniasis devel-
oped by Dye compared the efﬁcacy of various control methods in
the reduction of human and canine incidence of the disease (Dye,
1996). According to this model, and regarding the canine inci-
dence, killing infected dogs is the least successful strategy while
an effective veterinary drug should perform better, even with the
conservative assumption that only infectious dogs are treated. A
dog vaccine has higher impact, because it is prophylactic and the
insecticide treatment would be the best approach for dogs. The
expected outcome of control on human incidence is that killing
dogs is again the least successful strategy and that immunizing
people is less effective than immunizing dogs because it has no
impact on the dynamics of infection in the dog population. The
insecticide control would be the most effective strategy.
We used the data of human and canine incidence obtained
before and after Leishmune® vaccination in Araçatuba and Belo
Horizonte (Palatnik-de-Sousa et al., 2009) in order to see if they are
related towhat expected according the controlmodel of Dye (1996;
Figures 1A,B). The expected efﬁcacy for the vaccine in bringing
down the canine incidence of the disease is disclosed by plotting
along the y axis the incidence of VL in dogs after vaccination
divided by its value before vaccination and expressed as a percent-
age, and in the x axis the fraction of the susceptible dogs converted
to resistant by the vaccine treatment (Dye, 1996). In Araçatuba,
Brazil, the VL incidence in dogs after vaccination was 21.77%
(2006) and before vaccination 30.01% (2003) giving a percent
ratio of 72.54% which corresponds to a transformation of 25%
of the dog population from susceptible to resistant or protected
(Palatnik-de-Sousa et al., 2009; Figure 1A). This was achieved vac-
cinating only 7.531% of the dog population. In Belo Horizonte,
on the other hand, the decline in human incidence was observed
after dog vaccination in several districts. In the Nordeste district,
human cases declined from 24 to 18 giving a percent ratio of 72%
which corresponds to 28% of the human population moving to a
resistant class (Palatnik-de-Sousa et al., 2009; Figure 1B). This was
achieved by vaccinating only 11.03% of the whole dog population.
The other second-generation vaccine,LiESAp, composed of the
54-kDa excreted protein of L. infantum plus MDP also reached
Phase III trials after a kennel assay against L. infantum infection
(Table 1). Parasites were detected in the bone-marrow of 3/3
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FIGURE 1 | Impact of the use of Leishmune® vaccine on the
decrease of dog and human incidence of ZVL in Brazil.The curves
show the expected efﬁcacy of different control methods in bringing
down the (A) prevalence of infectiousness in dogs, and (B) the incidence
of human visceral leishmaniasis according to the model of Dye (1996).
The y -axes show the stable prevalence (A) or incidence (B) after control,
divided by the respective values before control, and expressed as a
percentage and the X axes record the percent change promoted by each
control method of control moving a fraction of susceptible dogs or
people to the resistant class. The arrows show the percent of dog (A)
and human (B) incidence after/before Leishmune® vaccination in
2004–2006 and their respective plot of the percent of dog (A) and
human (B) population that became protected and resistant to infection
after vaccine treatment.
placebo treated controls, while they were absent in 3/3 vaccinated
dogs (Lemesre et al., 2005). The double blind random trial fur-
ther performed with LiESAp+MDP in naturally exposed dogs of
South France revealed that after 2 years, an incidence of infection
of 0.61% (1/165) in vaccines versus 6.86% (12/175) in control dogs
making a 92% VE (Lemesre et al., 2007). In any dog showing clin-
ical and/or serological evidence, infection was conﬁrmed by the
presence of parasites in bone marrow aspirates cultured in NNN
media and also by PCR analysis (Lemesre et al., 2007). Differently
from what was described for the FML–saponin vaccine (da Silva
et al., 2001; Borja-Cabrera et al., 2002, 2008), the LiESAp vac-
cine induced protection against infection (Lemesre et al., 2007)
but not against severe disease or death by VL. No obits at all,
were described in the 2 years LiESAp assay (Lemesre et al., 2007),
pointing to the lower infective pressure of the endemic region.
The immune response generated in the LiESAp vaccinated dogs
was conﬁrmed by the ﬁnding of: a signiﬁcant leishmanicidal effect
of macrophages due to an IFN-γ dependent activation; a NO-
mediated apoptosis of intracellular amastigotes (Holzmuller et al.,
2005), a strong and long-lasting CMI revealed by positive IDR, an
anti-leishmanial activity ofmonocytes, andby the in vitro activities
of the anti-LiESAp antibodies (Bourdoiseau et al., 2009).
In Europe, a formulation related to the LiESAp vaccine was
licensed for commercialization under the name of CaniLeish®, in
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early 2011 and is currently being launched in Portugal, Spain,
France, Greece, and Italy. It is as a second-generation deﬁned
peptidic antigen composed of Excreted–Secreted proteins of the
supernatant of cultures of L. infantum. Differently from what was
published before (Holzmuller et al., 2005; Lemesre et al., 2005,
2007; Bourdoiseau et al., 2009) this formulation does not include
MDP but the QA21 adjuvant of Q. saponaria Molina instead
(Virbac, 2011; Table 1).
As explained by WHO guidelines (WHO, 1997), conﬁrmation
of infection by very sensitive methods such as PCR or culture
(Lemesre et al., 2005, 2007) represents a very early end-point of the
development of the disease, while kala-azar obits and severe clini-
cal cases (da Silva et al., 2001; Borja-Cabrera et al., 2002) are distant
end-points which occur much later in the development of infec-
tion. A comparison between efﬁcacies of Leishmune® and LiESAp
should only be performed using the same infective pressure and
the same end-point targets (WHO, 1997).
Finally, a vaccine called Leish-Tec® was also licensed in Brazil.
It is composed of the recombinant A2-antigen of Leishmania
amastigotes and is adjuvanted by saponin (Fernandes et al., 2008).
While protection due to the Leishmune® vaccine has been exten-
sively investigated in laboratory models (reviewed by Palatnik-de-
Sousa et al., 2008), explained through an immunological approach
(Araújo et al., 2008, 2009, 2011), and reported in: control versus
trial-ﬁeld assays with cohorts including 117 (da Silva et al., 2001),
85 (Borja-Cabrera et al., 2002), 72 (Nogueira et al., 2005), and 1138
dogs (Parra et al., 2007; Borja-Cabrera et al., 2008); immunother-
apy assays with 66 (Borja-Cabrera et al., 2010) and 24 dogs (Santos
et al., 2007); and in 19,392 vaccinated dogs in two Brazilian towns
(Palatnik-de-Sousa et al., 2009), there is only one report of an
experimental kennel assay with Leish-Tec® which was tested on
seven dogs and compared with four untreated controls (Fernan-
des et al., 2008). There is no information about the infectivity of
the strain used for challenge in that study and the lack of deaths
in the control animals suggests that the challenge was mild. There
are no reports of controlled-trial-ﬁeld studies with Leish-Tec®,
but despite the lack of peer-reviewed scientiﬁc publications, the
vaccine was licensed in Brazil in 2008.
Since it was demonstrated that a canine vaccine promotes a
decrease in the human and canine incidence of ZVL (Palatnik-de-
Sousa et al., 2009), an increase in vaccine coverage for dogs, espe-
cially in the absence of a licensed human vaccine for leishmaniasis,
would certainly bring about an interruption of epidemics.
VACCINES FOR CANINE LEISHMANIASIS UNDER
DEVELOPMENT
The L. braziliensis lysate of a ﬁrst generation vaccine against
CL, which failed to show efﬁcacy against canine ZVL when for-
mulated with BCG, is now under research but adjuvanted with
saponin (Giunchetti et al., 2007, 2008b). The vaccine increased the
anti-Leishmania IgG isotypes, together with higher levels of lym-
phocytes, particularly circulating CD8(+) T-lymphocytes, and L.
chagasi antigen-speciﬁc CD8(+) T-lymphocytes, as expected for a
Q. saponaria saponin containing vaccine (Giunchetti et al., 2007).
When combined to sand-ﬂy saliva proteins it revealed an addi-
tional increase in circulating CD21+ B-cells, CD5+, and CD4+
T-cells (Giunchetti et al., 2008b).
There is a general consensus stating that the capacity to respond
to multiple antigens may be an essential requisite of an efﬁca-
cious vaccine (Working Group on Research Priorities for Devel-
opment of Leishmaniasis Vaccines et al., 2011). Multiple antigens
are included in a ﬁrst generation or second-generation complex
vaccines such as Leishmune® or LiESAp (Lemesre et al., 2007;
Palatnik-de-Sousa et al., 2008) that already showed strong efﬁcacy
in ﬁeld assays. However, from the industrial point of view, obtain-
ing of protozoa vaccines has some limitations. Growing protozoa
and extracting native antigens is laborious, expensive, and requires
additional bovine products that are forbidden to be used since the
emergence of bovine spongiform encephalopathy. On the other
hand many subunits of Leishmania antigens have already been
described, used alone, or in combination and are even available in
the recombinant form (reviewed by Palatnik-de-Sousa et al., 2008;
Working Group on Research Priorities for Development of Leish-
maniasis Vaccines et al., 2011). These deﬁned vaccines could be
used in future multiple recombinant vaccines against canine ZVL.
The most promising candidates seem to be the LACK, LeIF,
TSA, LmSTI1, H1, Cpa+CPb, KMP11, and NH36 (reviewed by
Palatnik-de-Sousa, 2008). The last approach in second-generation
vaccines is the use of recombinant proteins that were tested in
kennel assays in a dog model against ZVL (Molano et al., 2003;
Fujiwara et al., 2005; Gradoni et al., 2005; Poot et al., 2006;Moreno
et al., 2007). None have advanced to Phase III dog trials. The
multicomponent Leish-111f fusion protein containing the anti-
gens TSA, LmSTI1, and LeIF, in formulation with MPL-SE or
AdjuPrime, was immunogenic in dogs challenged with L. cha-
gasi (Fujiwara et al., 2005) and L. infantum (MML; Moreno et al.,
2007), but failed to prevent L. infantum natural infection, or dis-
ease progression in dogs in an open kennel trial (Gradoni et al.,
2005). However it was useful as an adjunct therapy together with
Glucantime in treating a ﬁeld population of dogs suffering from
ZVL due to L. chagasi infection (Miret et al., 2008). The vacci-
nation was safe and induced a twofold to threefold increase in
antigen-speciﬁc proliferative response in vitro after cure, but was
lacking a clear clinical beneﬁt (though the trial was not powered to
reveal small effects; Kaye and Aebischer, 2011). Leish-110f in the
form of an experimental vaccine designated MML was also tested
alongside recombinant L. infantum histone H1 and hydrophilic
acylated protein B1 (HASPB1; Moreno et al., 2007) as prophy-
lactic vaccines against experimental ZVL. Dogs were vaccinated
with either MML adjuvanted with MPL-SE or H1 or HASPB1
adjuvanted with Montanide-ISA 720 and subsequently challenged
with 108 L. infantum promastigotes. All vaccines were immuno-
genic, however they developed different boost responses after
infection. For example, MML antibody responses were strongly
boosted, HASPB1 responses weakly so and H1 response unaf-
fected by infection (Moreno et al., 2007). Fewer H1 and HASPB1
immunized dogs developed CVL symptoms (37 and 50%, respec-
tively) compared with control or MML-vaccinated dogs (71 and
75%, respectively), but larger studies would be needed to conﬁrm
the efﬁcacy of these vaccines (Palatnik-de-Sousa et al., 2008; Kaye
and Aebischer, 2011; Working Group on Research Priorities for
Development of Leishmaniasis Vaccines et al., 2011).
Compared to recombinant protein vaccines, DNA vaccines are
much more stable and have the advantage of low production costs,
www.frontiersin.org April 2012 | Volume 3 | Article 69 | 9
Palatnik-de-Sousa Vaccines for canine leishmaniasis
no need for cold chain distribution, and the ﬂexibility of combin-
ing multiple genes in a simple construct. A lot of interest has
been generated for the development of a vaccine against leish-
maniasis in recent years, with studies going on in the labs on
experimental models. LACK, LeIF, TSA, LmSTI1,H1, CpA+CpB,
KMP11, and NH36 are the most promising candidates that may
ﬁnd a place in the forthcoming years, since they have already been
tested in various animal models (reviewed by Palatnik-de-Sousa,
2008).
Immunization with HPB-LACK protected dogs against ZVL
(Ramiro et al., 2003) by increasing the IFN-γ and IL-12 expres-
sion, lymphocyte proliferative response, and the IgG2 to IgG1 ratio
and it led to decreasing clinical symptoms, number of parasites
in target tissues, and IL-4 expression. A prime boost vaccina-
tion with CpA+CpB, Montanide 720, and CPG protected dogs
against ZVL, as evidenced by the increase in IgG2 speciﬁc anti-
body synthesis, lymphocyte proliferation, IFNγ/IL-10 secretion,
and DTH response (Rafati et al., 2005). No death or clinical signs
were reported, probably due to the very low infective challenge
(5× 106 promastigotes). Eight out of 10 vaccinated dogs were
considered protected based on their PCRnegative results; however,
no signiﬁcant conclusion could be drawn from the study, because
it used only two untreated control dogs (Rafati et al., 2005). A
cocktail of plasmid DNA encoding KMPII, TRYP, LACK, and
GP63 did not protect dogs against L. infantum virulent challenge
(Rodríguez-Cortés et al., 2007b).
Recently, a dominant antigen in the FML complex, a nucle-
oside hydrolase of 36 kDa, has been shown in the recombinant
form or as a DNA vaccine to reproduce some of the Leishmune®
effects in mice (Aguilar-Be et al., 2005). The NH36 DNA vac-
cine protected mice against infection by L. chagasi, Leishmania
mexicana (Aguilar-Be et al., 2005), and Leishmania amazonen-
sis (Souza and Palatnik-de-Sousa, 2009), indicating its potential
usefulness in a bivalent immunoprophylactic vaccine for the con-
trol of both endemics. Protection by the DNA vaccine was higher
than that induced by the recombinant NH36 or the FML anti-
gen plus saponin, and it is related to IFN-γ-producing CD4+
T-cells, which are characteristic of a TH1 type immune response
(Aguilar-Be et al., 2005). The DNA vaccine showed prophylac-
tic and immunotherapeutic effects against ZVL in a kennel assay
(Borja-Cabrera et al., 2009, 2012). The immunotherapy treatment
increased survival and reduced clinical status of L. chagasi-highly
infected dogs through the enhancement of aNH36-speciﬁc CD4+
T-cell response (Borja-Cabrera et al., 2012).
The protection induced by the NH36 recombinant vaccine
is related to its C-terminal domain bearing the required T-cell
epitopes that are responsible for a main CD4+ T-cell-mediated
immune response that has the enhancement of the IDR reac-
tion and the increases in ratios of TNFα/IL-10 CD4+ producing
cells as strong correlates of protection (Nico et al., 2010). The less
deﬁned but nevertheless effective Leishmune® vaccine may there-
fore become replaced by a synthetic product comprising its active
ingredients (Kaye and Aebischer, 2011).
The control of the companion dog population for VL is funda-
mental in order to avoid the spread of the disease between humans
and dogs.A high level of infection in dogs, particularly in impover-
ished areas, just before the start of the human epidemic, or during
the epidemic, or a rising prevalence of canine infection before the
epidemic all strongly predicted a high incidence of human VL
(Werneck et al., 2007). Recent research demonstrates that the use
of insecticides both in residences and in impregnated dog neck-
laces and/or the use of preventive canine vaccine could potentially
substitute the dog culling contributing to the eradication of the
disease. In any case, the research on human vaccines and the large
use of canine vaccines against VL should be stimulated in order to
reduce the incidence of both the canine and human disease.
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